IMM02‑KORA / Immunis, Toray - LARVOL DELTA

Immunis Licenses Treatment Candidate for Dyskinesia Associated with Parkinson’s Disease (Businesswire) - "Immunis will continue its development under the name 'IMM02‑KORA' or 'KORA'...Under the terms of the agreement, Immunis obtained exclusive rights to develop and commercialize 'KORA' in the United States, Canada, the European Union, and the European Free Trade Association. Immunis has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial."

IND • Licensing / partnership • Parkinson's Disease